MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo
MK-2206 是一种变构 Akt 抑制剂，可在体内外通过标准化疗药物或分子靶向药物增强抗肿瘤功效
期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-09-1012
Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, Katsuyoshi Miyama, Shunsuke Taguchi, Kyoko Tsujioka, Yoko Ueno, Harold Hatch, Pradip K Majumder, Bo-Sheng Pan, Hidehito Kotani
